Federal Judge Urges Novartis to Drop Financial Ruin Claim Amid Generic Drug Competition

A D.C. federal judge has advised Novartis to abandon claims that it would face financial ruin if a generic version of its top-selling drug, Entresto, entered the market. The judge noted that Novartis would still maintain financial stability even if it lost $3 billion in U.S. sales, given its substantial $45 billion global revenue. For more on this development, please refer to the detailed article here.